| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Models |
From the Center for Research on Reproduction and Women’s Health;* the Cellular and Molecular Biology Program and Department of Genetics; the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology; and the Abramson Family Cancer Research Institute; University of Pennsylvania, Philadelphia, Pennsylvania
Abstract
Vascular endothelial growth factor (VEGF) performs multifaceted functions in the tumor microenvironment promoting angiogenesis, suppressing anti-tumor immune response, and possibly exerting autocrine functions on tumor cells. However, appropriate syngeneic animal models for in vivo studies are lacking. Using retroviral transfection and fluorescence-activated cell sorting, we generated a C57BL6 murine ovarian carcinoma cell line that stably overexpresses the murine VEGF164 isoform and the enhanced green fluorescent protein. VEGF164 overexpression dramatically accelerated tumor growth and ascites formation, significantly enhanced tumor angiogenesis, and substantially promoted the survival of tumor cells in vivo. In vitro, VEGF164 overexpression significantly enhanced cell survival after growth factor withdrawal and conferred resistance to apoptosis induced by cis-platin through an autocrine mechanism. VEGF/green fluorescent protein-expressing tumors were not recognized by the adaptive immune system. After vaccination, a specific anti-tumor T-cell response was detected, but tumor growth was not inhibited. This engineered murine carcinoma model should prove useful in the investigation of the role of VEGF in modulating the tumor microenvironment and affecting the complex interactions among angiogenesis mechanisms, anti-tumor immune mechanisms, and tumor cell behavior at the natural state or during therapy in ovarian carcinoma.
This article has been cited by other articles:
 |
|
 |
|
  E. Huarte, J. R. Cubillos-Ruiz, Y. C. Nesbeth, U. K. Scarlett, D. G. Martinez, R. J. Buckanovich, F. Benencia, R. V. Stan, T. Keler, P. Sarobe, et al. Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity Cancer Res., September 15, 2008; 68(18): 7684 - 7691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed Normalization of the Ovarian Cancer Microenvironment by SPARC Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice Cancer Res., June 15, 2007; 67(12): 5708 - 5716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hara, S. Samuel, J. Liu, D. Rosen, R. R. Langley, and H. Naora A Homeobox Gene Related to Drosophila Distal-Less Promotes Ovarian Tumorigenicity by Inducing Expression of Vascular Endothelial Growth Factor and Fibroblast Growth Factor-2 Am. J. Pathol., May 1, 2007; 170(5): 1594 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells Cancer Res., April 15, 2007; 67(8): 3683 - 3690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cao, R. C. Savani, M. Fehrenbach, C. Lyons, L. Zhang, G. Coukos, and H. M. DeLisser Involvement of Endothelial CD44 during in Vivo Angiogenesis Am. J. Pathol., July 1, 2006; 169(1): 325 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Su, Q. Zheng, M. M. Vaughan, Y. Bu, and I. H. Gelman SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor Inhibition Cancer Res., June 1, 2006; 66(11): 5599 - 5607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fang, C. Xia, Z. Cao, J. Z. Zheng, E. Reed, and B.-H. Jiang Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways FASEB J, March 1, 2005; 19(3): 342 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Weis, J. Cui, L. Barnes, and D. Cheresh Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis J. Cell Biol., October 25, 2004; 167(2): 223 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, N. Yang, D. Katsaros, W. Huang, J.-W. Park, S. Fracchioli, C. Vezzani, I. A. Rigault de la Longrais, W. Yao, S. C. Rubin, et al. The Oncogene Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma Cancer Res., July 15, 2003; 63(14): 4225 - 4231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, N. Yang, J.-W. Park, D. Katsaros, S. Fracchioli, G. Cao, A. O'Brien-Jenkins, T. C. Randall, S. C. Rubin, and G. Coukos Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer Cancer Res., June 15, 2003; 63(12): 3403 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, N. Yang, J.-R. Conejo-Garcia, D. Katsaros, A. Mohamed-Hadley, S. Fracchioli, K. Schlienger, A. Toll, B. Levine, S. C. Rubin, et al. Expression of Endocrine Gland-derived Vascular Endothelial Growth Factor in Ovarian Carcinoma Clin. Cancer Res., January 1, 2003; 9(1): 264 - 272. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
